MAIA Biotechnology Hits Key Enrollment Milestones in NSCLC Trials…

Event summary

MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial, evaluating ateganosine with cemiplimab in NSCLC.
THIO-104 Phase 3 trial has enrolled 65% of its 100-patient target for 2026, with interim analysis planned for 2027.
THIO-101 showed 90.5% interim disease control rate, nearly triple the standard-of-care chemotherapy outcome.
FDA granted Fast Track designation to ateganosine in July 2025, enabling accelerated review and potential marketing exclusivity.

The big picture

MAIA Biotechnology is advancing its novel telomere-targeting immunotherapy, ateganosine, through critical clinical milestones in non-small cell lung cancer. The company’s Phase 2 data suggests a potential breakthrough for third-line NSCLC patients, addressing a significant unmet need. The FDA’s Fast Track designation accelerates the path to market, but competition in immuno-oncology remains fierce.

What we're watching

Clinical Efficacy: Whether ateganosine’s Phase 2 results will translate into Phase 3 success and regulatory approval.
Enrollment Pace: The pace at which MAIA can maintain its aggressive enrollment timeline for THIO-104.
Competitive Positioning: How MAIA differentiates ateganosine in the crowded NSCLC treatment landscape.